58349-23-8

Usage

Uses

Used in Pharmaceutical Industry:
Rotigotine is used as a therapeutic agent for the treatment of Parkinson's disease and restless legs syndrome. It functions by activating dopamine receptors in the brain, which aids in managing the motor symptoms of these conditions, such as tremors, rigidity, and bradykinesia.
Used in Transdermal Drug Delivery:
Rotigotine is utilized as an active ingredient in transdermal patches, providing a continuous and controlled release of the medication over a 24-hour period. This method of administration ensures consistent drug levels in the bloodstream, enhancing patient compliance and convenience.
Used in Neurological Treatment:
Rotigotine is employed as a neuroregulatory agent, specifically targeting the dopaminergic system to alleviate the symptoms of Parkinson's disease and restless legs syndrome. Its long half-life and well-tolerated nature make it a suitable option for long-term management of these conditions.
Common side effects associated with Rotigotine use include nausea, dizziness, and reactions at the application site. However, its effectiveness in treating the symptoms of Parkinson's disease and restless legs syndrome makes it a valuable asset in the pharmaceutical industry.

InChI:InChI=1/C18H21NO/c1-20-18-9-5-8-15-12-16(10-11-17(15)18)19-13-14-6-3-2-4-7-14/h2-9,16,19H,10-13H2,1H3/t16-/m0/s1

Upstream product

• 136247-07-9 2-(N-benzylamino)-5-methoxytetralin 
• 100-46-9 benzylamine 
• 58349-24-9 C₈H₈O₃*C₁₈H₂₁NO 
• 32940-15-1 5-methoxy-2-tetralone 

Downstream Products

• 101403-24-1 (S)-(5-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propylamine hydrochloride 
• 101470-23-9 Desthienyl-Rotigotine 
• 1089179-55-4 (6S)-6-[benzylamino]-5,6,7,8-tetrahydronaphthalen-1-ol 
• 136247-11-5 N-((S)-5-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-2-(4-nitro-phenyl)-N-propyl-acetamide 
• 136316-06-8 (S)-(-)-2--5-methoxytetralin 
• 129388-80-3 (S)-(-)-2--5-hydroxytetralin 
• 101403-23-0 (-)-(2S)-2-(N-benzyl-N-n-propylamino)-5-methoxytetralin 

Relevant academic research and scientific papers

Heterocyclyl-substituted-tetrahydro-naphthalen derivatives as 5-HT7 receptor ligands

The present invention relates to heterocyclyl-substituted-tetrahydro-naphthalen compounds of general formula (I) and (Iprot), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans or animals, mediated by the receptor 5-HT7 affinity.

Combination of a 5-HT7 receptor ligand and an opioid receptor ligand

The present invention refers to a combination of a 5HT7 receptor ligand and an opioid recptor ligand, especially of a 5HT7 receptor agonist and an opioid recptor agonist, a medicament comprising this combination, or the use of this combination for the treatment of the symptoms of pain, the prevention or the prophylaxis of the symptoms of pain.

Fluorescent Probes for Dopamine Receptors: Synthesis and Characterization of Fluorescein and 7-Nitrobenz-2-oxa-1,3-diazol-4-yl Conjugates of D-1 and D-2 Receptor Ligands

Fluorescent probes have been designed and developed for dopamine D-1 and D-2 receptors.Fluorescein and/or NBD (7-nitrobenz-2-oxa-1,3-diazol-4-yl)derivatives of PPHT (D-2 agonist), spiperone (D-2 antagonist), SKF 38393 (D-1 agonist), and SKF 83566 (D-1 antagonist) were synthesized via their amino-functionalized analogues and all ligands were pharmacologically evaluated by measuring their ability to displace SCH 23390 and 3H)spiperone from D-1 and D-2 receptor sites in caudate putamen of monkeys (Macaca fascicularis).The fluorescein derivatives of PPHT andSKF 83566 and the NBD derivatives of spiperone and SKF 83566 retained the high affinity and selectivity of parent ligands.The NBD derivatives of PPHT showed higher D-2 receptor affinity and selectivity than their parent ligands.The enantiomers of the fluorescent derivatives of PPHT were also synthesized and were found to exhibit stereoselectivity in binding to the D-2 receptor, with the S enantiomers having a considerably higher affinity than their R analogues.In contrast to these results, the fluorescein derivative of SKF 38393 showed only a low affinity for the D-1 receptor.These fluorescein- and NBD-coupled D-1 and D-2 receptor ligands have considerable significance as potential probes in the study of distribution of the receptors at the cellular/subcellular level and of their mobility in membranes in normal/diseased states by use of fluorescence microscopic and fluorescence photobleaching recovery techniques, respectively.The development of these novel fluorescent probes should also provide new leads for the design and synthesis of additional fluorescent ligands with better fluorescent properties and/or higher affinity/selectivity for the DA receptors.